A transient. hyporegenerative ancmia is a common problem anlong small. preterni infants. particularly those born at lcss than 3 1 \~l i of gestation ( 1 . 2). This anemia is referred to as "anemia of prematurity," and is a normocytic. norn~ocliromic ancnlia with low rcticulocytc counts, inappropriately low EPO seruni levels: it is often apparent by the 3rd or 4th u k of life (3. 4). In addition. an early iatrogenic ancmia occurs from blood samples that are taken for a variety of laboratory tests. Some infants tolcratc this condition without apparent difliculty. but others arc synlptomatic. and this can be ameliorated by cnthrocytc transfusion (5) . Thus. vcry small premature neonates are among the most common of all patient groups to undergo extensive transfusion and the number of blood transfusions given in neonatal intensive care units has increased as the surviv;il of vcry in~nia-turc infants has improved (6) . Red ccll transfusion entails a considerable risk to snlall babies (7) . Recently. r-IIuEPO. a new therapeutic option in anemia. has been of great interest to neonatologists because it may prove to be an efli.ctivc alternative to blood transfusions, inasmuch as infants with AOP have low EPO levels. reduced bone nlarrow cnthroid precursors. and abundant EPO-sensitive cnthroid progenitors (8) (9) (10) .
The results of the first clinical trials regarding the response and tolcrancc to EPO in infants have been publislicd ( 1 1-17). However, the original dosage, the time and mode of administration (i.c. preventive or therapeutic). and the treatnlcnt regimen have yet to be defined (18) (19) (20) .
We report a randomizcd controlled study of r-I~luEl'O early prcventivc administration in small premature infants \\.ho \vcrc highly likely to rccluire transfusions for AOP.
Slrl!jcc<~.v. Forty-four premature infants entered a randomizcd. controlled trial after their parents gave informed consent in accord:incc ~vith the ethics comnlittce of our institution. The infants wcrc randomly assigned to receive (EI'O group: 1 5 nconates) or not receive (CON group: 19 neonates) r-IluEPO according to a schedule generated by a random-number table. The doctors in clinical charge lverc unatvare of the treatment or control status of the babies.
Infants ~vcrc eligible for the study if they fulfilled all the follo\ving criteria: I ) gestational ;igc at birth 5 3 1 \vk: 2 ) birth weight 5 1500 g; 3) aged I to 7 d: 4 ) no histon of significant hemolytic disease caused by glucose 6-phosphate dcliydrogcnasc deficiency or ABO or Rh incompatibility: and 5 ) clinical stability at entry as judged by the absence of electrolyte-acid base disturbances. absence of acquired or congenital infections. good oxygenation either in mechanical ventilation or not. and abscncc of seizures and hypertension Given that EPO treatment was started during the 1st wk of life. it was not possible to anticipate the probability of developing complications. For this reason, at the end of the therapy, to bcttcr assess in which nconatcs EPO trcatmcnt was cfrectivc, we classified the EPO and CON groups into uncomplicated (A) and complicated (B) nconates. Neonates without or with minimal signs of respiratory distress and with no signs of sepsis \vcrc considcrcd uncomplicated. whereas neonatcs requiring mechanical ventilation (respiratory distrcss syndrome, apnca, and sepsis) for more than 3 d were characterized as complicated.
Dnr,y rrrIt)~ir~i.srrrrriot~. We used r-HuEPO manufactured by Cilag A.G. (Zug. Slvitzerland) as a buffered solution containing 2000 U/mL of r-HuEPO. After 1:1 dilution with 0.9% saline solution, a solution of 1000 U/mL was obtaincd that was more suitablc for administration to small infants. Starting at 3-7 d of life, r-HuEPO wasgivcn s.c. twice weekly up to 6 \vk of postnatal age at a dosage of 150 U/kg body wcight per dose. All the paticnts had oral supplcnicnts of clcmcntal iron 3 mg/kg/d from the 15th d of life that wcrc continued at the discretion of the attending neonatologist. The most conlmon rcason for temporarily discontinuing iron therapy was suspected sepsis or nccrotizing cntcrocolitis. Infants initially wcrc on total parcnteral nutrition, consisting of carbohydrates 15 g/kg/d, proteins 2 g/kg/d. and fat ? g/kg/d. Thereafter. depending on thcir clinical condition. they received a special formula for prematurc nconatcs that contained 2 g of protein per 100 mL. They also received I m L of multivitamins pcr d and vitamin E (5 U/d) as part of the standard nursery care. In a11 infants. r-tluEPO therapy was administered in thc hospital.
Luhorrrtorj, rrtltl c.litli(~I t)~otli/orit~,y. The follo\ving data ucrc recorded before, during, and at completion of treatment, and at up to 6 mo of age: daily vital signs with blood pressures obtained with an automatic noninvasive oscillomctric monitor (Dinamap 847. Criticon). number and duration of apncic episodes. bradycardias or tachycardias. daily weights, caloric intake, cerebral sonograms, and transfusion requirements. Transfusions were ordered by the clinicians caring for each infant without consulting the investigators. based on general guidelines for cqthrocytc transfusions (6. 2 1). According to these guidelines. neonates who wcrc well were transfused if thcir hcmatocrit was less than 0.25 combined with signs rcfcrablc to thcir anemia, such as poor wcight gain. persistent episodes of bradycardia or tachycardia. and apnea. Neonates with scvcre respiratory disease (BPD). particularly those requiring oxygen and/or ventilator support. received transfusions to maintain their hcmatocrit level at greater than 0.40 (6) .
Blood samples wcre obtaincd at cntry. \vcekly. during the 6-wk trcatmcnt, and thereafter at 3 and 6 m o of chronologic age for determination of hematocrit, H b concentration, and coniplctc blood cell counts including reticulocytes (percentage). thrombocytes. smear examinations, serum levels of ferritin, fetal H b cytochcmistry data by acid elution, and serum EPO levels by RIA (22) . For rcticulocytc and H b F-containing erythrocyte counts. 2000 and 400 cells wcrc counted, rcspcctivcly. and a11 determinations wcrc done blindly and in duplicate. Blood was obtaincd cvcry Monday morning and EPO was given cvcry Tuesday and Friday morning.
Sirr/isiic.rrl unrr1j:si.s. All statistical comparisons betwccn treatment and control groups wcrc performed with the / test.
RESULTS
I'uiiilni c~l~urrrc?cri.s~it:v. rrrlrl xro\t'/l~. Thcrc were no significant differences betwccn the group of infants randomly assigned to receive or not receive r-HuEPO in birth weight, gestational age, initial hcmatocrit, reticulocyte count, scrum ferritin conccntration, or scrum erythropoietin concentration. Table 1 summari;lcs charactcristics at entry.
In group A, no children were mechanically ventilated. The mean timc of full cntcral feeding establishment was similar, 13 + 5.4 d and 13.3 + 7.5 d in the EI'O A and CON A groups, respectively. In two nconatcs. one from each group. full entcral feeding was established on the 26th d of life b e c a~~s e they had gastrointcstinal problems (feeding intolerance, abdominal distcnsion). A CON A neonate had an episode of urinary tract infcction. Mean hospitalization time and rate of weight gain ivcrc similar for the t\vo groups.
In group B, thcrc wcrc no significant difTerences between EPO and control paticnts with respect to nicchanical \entilation duration. total parcntcral nutrition duration, mean nursing time, or rate for \vcight gain (Table 2) . Ttvo babies assigned to the EPO B group died of BPD, one at 7 wk of age and the other at 4 nio of age: thcrc was one control infant who also died of BPD. We observed no complications clearly attributable to [!PO therapy.
At 3-6 mo of age. the rate of \veight gain \vas siniilar in EPO and CON babics.
Ile1t~~crio1o~yic~ t~r e~r r . s r r r c l~~~~~t~i I s Y
There were no significant dill'ercnccs in hcmatocrit and l l b values bctwecn EPO and CON babies (both uncomplicated and complicated) at any time during the study from birth until 6 nio.
Prctrcatment rcticulocyte counts were similar at cntry in a11 infants (Table 1) . Tlic initial fall in the rcticulocytc count in both EPO and CON groups was followed by a marked increase in the EPO groups (both A and B) compared \vith the CON groups (Figs. I and 2). Mcan reticulocytc counts (7;) \vcre significantly higher in EPO infants compared with control infants. At 3 and 6 mo of age. thcrc ivere no dill'crences between EI'O and CON groups in rcticulocyte counts (Figs. I and 2 ).
There were no significant changes in platelet counts in cithcr group throughout the study period. Also, there wcrc no signilicant difkrences between EI'O and control patients with respect to total leukocyte counts or absolutc neutrophil counts. No infant had an absolute neutrophil count of < I x 1Oq/1-during EPO trcatmcnt. Table 2 summarizes the hematologic parameters at thc end of r-HuEPO therapy.
At cntry. H b F levels \vcrc similar in both EI'O and CON uncon~plicated infants (94 and loo%, respectively). The observed significant decrease in the level of HbF in the CON A group froni the 4th wk compared with the EPO A group was strongly correlated with the increased transfusion in the control babies. HbF Ic\,cls in conlplicatcd nconates at the end of the study \vcrc very low. reflecting the high transfusion rate in this group. tIbF in EPO B group was significantly higher at the 6th wk comparcd with the CON B group.
Illoorl .srrtj~plitlg rrtlrl irrrrr.yfir.sior~.s. Volun~es of blood removed for laboratory tests and the amounts transfused in the studied groups arc shown in Table 3 . Thcre was a significl~nt decrease in transfusions in EPO \lcJr.slr.s CON uncomplicated neonates (EI'O A: 0.44 f 0.73, CON A: 1.28 + 0.75). Only three ofninc neonatcs in the uncomplicated EPO group received four transfusions comparcd \vith six of seven nconatcs of the control uncomplicated nconates, who rcceivctl nine transfusions. One of the three EPO A nconatcs who received transfusions had t\vo transfusions after the end of EPO trcatmcnt. one at the 7th \vk and another one at the l lth \vk. In the complicatcd neonates. there rvas a high incidence of transfusion without any difference between EPO and CON nconatcs despite the significant increase of rcticulocytc count in the EPO group (EPO B: 8.35 f 5. CON B: 7.75 ? 3.7).
Sc'r~rt)~ ,/i,rri/it~ /i,ri,l.s. At the beginning of the study, scruni ferritin levels wcrc similar in all patient groups. At the end of EPO trcatment, fcrritin levels in uncomplicated nconatcs were significantly lo\vcr comparcd with complicated nconatcs. In the EPO group of uncomplicatcd nconatcs. fcrritin decreased significantly compared with the control group from the 3rd wk. In complicated neonates, ferritin increased at the end of the study in both EPO and CON nconatcs. but the increase was lotvcr in the EPO group (Figs. 3 and 4) .
Scrrrtj~ IYPO 1crc~l.s. Mean EI'O levels at cntry, which was 3-7 d after birth. were similar in a11 study patients (10.5-14.7 U/L). In the EPO groups, levels were slightly elevated during the study compared with control groups, but the differences were not significant. An increase was observed in the EPO uncomplicated group at the 2nd wk and at the 2nd and 3rd wk in the EPO complicated groups. After 6 wk of therapy, the mean EPO value was I I U/L in EPO A. 5 U/L in CON A, I I U/L in EPO B. and 9 U/L in CON B groups (Table 2) . Subsequently, at 3 and 6 mo there were no significant differences in EPO levels between treated and control infants, indicating that treatment with rHuEPO had no effect on subsequent EPO production. In four infants from the EPO complicated group, we observed very high values (150-300 U/L): in two of those infants, the high values were associated with exchange transfusions that were performed for sepsis.
DISCUSSION
In healthy, premature neonates, red blood cell transfusions are usually administered between the 3rd wk of life and hospital w e e k : a f t e r b i r t h Fig. 2 . Reticulocytes (7;) in complicated neonates (conversion factor for SI. 0.0 I ).
8 IC normodischarge to treat the hyporegenerative .normoc)t' chromic AOP (23) . It has been suggested that AOP is caused by selective deficiency of EPO. The hypothesis that AOP is the result of defective response of erythroid progenitors to EPO plus deficient generation of multiple erythropoietic factors was excluded by studies of Shannon (11 rrl. (8) and Rhondeau (,I 01. (9) . They found normal responsiveness to EPO of burst-forming units-erythroid and colony-forming units-erythroid from verylow-birth-weight infants: also. the biologic activities of other factors responsible for early crythroid production, IL-3 and granulocyte-macrophage colony-stimulating factor, were not reduced in infants with AOP (24) .
In our study, the favorable effect of EPO on erythropoicsis is apparent from the early significant increasc in the reticulocyte count in both EPO groups (complicated and uncomplicated) compared with the control groups, but the need for transfusions was reduced only in uncomplicated EPO neonates. The levels of reticulocytes in the uncomplicated CON group were higher spontaneously than in the EPO complicated group. This finding most SOUBASI 1:'T :IL. w e e k s r f t e r b i r t h Fig. 3 . Serum ferritin levels (ng/mL. conversion factor 1.00 for j~g/ L) in uncomplicated neonatcs. likely was caused by the increased number of transfusions and possible infections that inhibited erythropoiesis in the complicated group. In complicated EPO neonates with respiratory problems, the end result of increased need for transfusions was related to altered indication for transfusion. In these neonatcs. it is customary to maintain hematocrit levels higher than 0.40 (6) . They also have large phlebotomy needs, which might limit or obscure their response to EPO (10) . Shannon ct (11. (12) . in a placebo-controlled study with mean age at entry 22 d, administered r-HuEPO to 20 small, premature infants who were highly likely to require erythrocyte transfusions for AOP. They, despite the observed reticulocytosis did not find reduced need for transfusions. The heterogeneity of patients in their study is a possible explanation for this finding. However, our study was designed to give EPO in a preventive rather than therapeutic mode. The transfusion limit of hematocrit 0.40 explains the low reticulocytc curve of the complicatcd control group. because such a high limit will depress erythropoiesis even in adults.
Ohls and Christensen (13) . like us, administered EPO in a higher dose to treat anemia in 20 infants, and their results are comparable to ours. All their neonates had at least one transfusion before the entry into the study. Probably with preventive EPO administration the neonates would not need any transfusion, because the end goal of EPO thcrapy is to reduce transfusions as much as possible because of their side effects. Such a goal is attractive, because 3% of infants who undergo transfusion have adverse effects (7) . In our study, one of the three neonates in the uncomplicated EPO group who received transfusions had two transfusions after the end of EPO treatment. Probably the duration of therapy for 6 wk is not ideal, and it should be altered according to individual clinical needs and laboratory findings. This is more likely the case for the complicatcd nconates, who should be treated with EPO until aftcr weaning from ventilation and improvement of clinical condition (25) .
The HbF values can be explained by the number of transfusions. but the increase of HbF after a fall of the initial values and the significantly higher HbF values in the EPO complicatcd group vcJr.slr.y the CON B group could be due to the effect of EPO in the pattern of synthesized H b (26) . This observation should be elucidated by further studies.
Another sign indicative of the hemopoietic effect of r-HuEPO is the gradual decline in scrum fcrritin levels in EPO groups compared with the CON groups that reflects the rapid mobilization of iron stores. Our results arc in agreement with the results reported by Halperin clt (11. (1 1). We did not carry out any studies of iron balance because we tried to minimize blood sampling. Although serum ferritin levels were lower in the EPO-complicated group compared with the control, a gradual increase of fcrritin in both EPO and CON complicated groups that was due to the high incidence of transfusion was observed.
Regarding the scrum EPO levels, there was no significant increase in serum EPO in the treated groups compared with the control infants not receiving the medication. There are two reasons for the lack of such an increase in serum EPO levels. First, in premature infants, low endogenous production of erythropoietin relative to the degree of anemia has been documented (27, 28) , and serum EPO levels are lower in the first 2 mo than at any other time in life (29). Premature infants arc similar to chronic renal failure patients in that they have a limited capacity to raise their EPO production sufficiently to compensate for their anemia (30) . Second, according to pharmacokinetic studies of EPO in children and adults with renal failure. an association between the timing and the route of administration (i.v. or s.c.) and serum EPO levels appears to exist, inasmuch as S.C. delivery resulted in serum values that peaked at 10 h and thereafter declined slowly with a tn of 2 1.1 f 4.5 h (3 1. 32). In our study. there was a n interval of about 72 h between EPO administration and blood sampling.
Erythropoietin in a dosage of 300 U/kg/wk had no adverse effects on leukocytes and thrombocytes. This observation is valuable, especially in uncomplicated nconates, because the course of these neonates was not associated with any problems that can influence leukocytes and platelets. Ohls and Christensen (1 3) could not clarify the mechanism responsible for neutropenia that was observed aftcr r-HuEPO with studies in bone marrow
